PCC – Reducing Treatment Burden in Retinal Disease Care with Extended-Duration Anti-VEGF Therapies

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, retina specialist John Kitchens, MD, has a conversation with a patient about the choice he made for anti-VEGF therapy to reduce his treatment burden, then discusses recent clinical trial data on therapeutic options with extended treatment intervals.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Identify unmet needs and treatment burden associated with conventional therapies for patients with DME and nAMD
• Evaluate recent clinical trials and real-world data on the safety, effectiveness, and durability of the ranibizumab port delivery system and other anti-VEGF therapies for patients with DME and nAMD
• Apply best practices to guide the use of the ranibizumab port delivery system and other anti-VEGF therapies when managing patients with DME and nAMD

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Genentech, Inc.

Chair:

John Kitchens, MD
Retina Associates of Kentucky
Eye Care Partners

Disclosures: Advisor, Consultant, Fee for Service Recipient: Alcon, Apellis, Astellas, Bayer, Roche Speakers Bureau: Apellis, Astellas, Bayer, Roche, Regeneron Ownership in Public Traded Companies: Vortex Surgical

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on educating patients on their anti-VEGF options, go to https://www.gotoper.com/courses/reducing-treatment-burden-in-retinal-disease-care-with-extended-duration-anti-vegf-therapies.

Release Date

June 30, 2026

Expiration Date

June 30, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.